business
developmentStatement of Intent
TransMolecular has developed a proprietary compound, TM601 (Chlorotoxin), for the treatment of various cancers and ophthalmologic, neo-vascular diseases. To protect its products and technology platforms in the US and worldwide, TransMolecular has established an early, strong, and dominant patent position with over 30 patents and patent applications, broadly covering the diagnosis and treatment of cancer. In addition, TransMolecular has outstanding internal resources with great expertise in research and product development and has established several important collaborations with leading public and private research centers to expand research capabilities and advance the development of the Company's platform.
TransMolecular is seeking strategic collaborations with partners looking to expand their pipelines. Contact our business team to learn more about partnering opportunities.
Contact Our Business Team
For additional information, please contact:
Business Development
TransMolecular, Inc.
1060 First Avenue
Suite 400
King of Prussia, PA 19406
USA
Phone: 610.768.8041
Fax: 610.337.9548
Email: collaborate@transmolecular.com